Certain genetic disorders cause widespread disease in the body, but the principle reason for illness and death in early childhood is failure of the blood system.  We would like to study these genetic blood disorders by “turning back the clock” – using new technology in stem cell biology to take skin cells from patients with genetic blood disorders and return them to an embryonic-like state, wherein they regain the ability to form any type of cell in the body. … Read more about Suneet Agarwal, MD, PhD

Our laboratory studies the genetic determinants of blood cell ontogeny and disease. We use molecular genetic, biochemical, and genome editing methodologies… Read more about Daniel E. Bauer, MD, PhD

Hematopoietic stem cell (HSC) progeny can represent a vehicle for therapeutic molecule delivery to the Central Nervous System (CNS) upon transplantation in… Read more about Alessandra Biffi, MD

Alan Cantor's laboratory is focused on further elucidating the transcriptional mechanisms that regulate normal hematopoiesis and how they may be perturbed in certain inherited platelet disorders and hematologic malignancies. … Read more about Alan Cantor, MD, PhD

The primary focus of the Ebert laboratory is the biology and treatment of clonal hematopoiesis and myeloid malignancies. Our genetic studies have led to the characterization of clonal hematopoiesis of indeterminate potential (CHIP) and the identification of mutations in MDS that predict overall survival, outcome following bone marrow transplantation, … Read more about Benjamin Ebert, MD, PhD

Our laboratory is interested in the transcriptional regulation of normal blood cell development and leukemia. All blood cells arise from a small population… Read more about Hanno Hock, MD, PhD

The Hoggatt Laboratory is broadly interested in the stem cell niche regulatory mechanisms that govern tissue regeneration, particularly regulation by… Read more about Jonathan G. Hoggatt, PhD

Our laboratory is interested in how immune responses in skin are initiated, and how T cell mediated memory responses occur in skin, and in particular a newly described population of antigen experienced T cells known as Resident Memory T Cell (TRM). … Read more about Thomas S. Kupper, MD

Our research focuses on using the zebrafish to better understand human cancer and to develop novel insights into how it is that tumors can be remade following conventional chemotherapeutic intervention. Uncovering the downstream molecular pathways that lead to relapse will be integral to identifying novel drugs for the treatment of cancer.… Read more about David M. Langenau, PhD

M. William “Willy” Lensch leads Harvard Stem Cell Science’s educational initiatives as Executive Director of the Harvard Department of Stem Cell and Regenerative Biology (HSCRB) and Co-director of the Harvard Stem Cell Institute Internship Program (HIP). … Read more about M. William Lensch, PhD

Our group is working on cancer genetics, using the zebrafish genetic system to clarify developmental pathways subverted in human leukemias and solid tumors… Read more about A. Thomas Look, MD

Stem cells and tissue engineering hold great promise in Regenerative Medicine. However, engrafting stem cells and generating tissues with stable functional… Read more about Juan M. Melero-Martin, PhD

Dr. North’s laboratory focuses on developmental hematopoiesis as a key to… Read more about Trista E. North, PhD

The laboratory utilizes multidisciplinary approaches to understand how mammalian cells choose specific fates and how mutations in important transcriptional regulators lead to developmental defects or malignancy.… Read more about Stuart Orkin, MD

Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used in the treatment of patients with hematologic malignancies, but continues to be associated with severe toxicities. Both the effectiveness and toxicity of HSCT are mediated by donor T-cells in the stem cell graft. Those T cells that target antigens expressed on recipient leukemia cells play an important role in eradicating residual tumor cells and preventing leukemia relapse after transplant. In contrast, T cells that target antigens expressed by normal tissues in the recipient are the primary mediators of graft versus host disease (GVHD) and thus lead to substantial toxicities. My laboratory focuses on the assessment of donor immune function after HSCT and characterization of the immune mechanisms responsible for graft versus leukemia (GVL) and GVHD.… Read more about Jerome Ritz, MD